HARVARD MEDICAL SCHOOL CURRICULUM VITAE
Date Prepared:
February 26, 2015
Name:
Lucy Hwa-Yue Young
Office Address:
Massachusetts Eye and Ear Infirmary
243 Charles Street, Boston, MA 02114
Work Phone:
617-573-3710
Work Email:
lucy_young@meei.harvard.edu
Work Fax:
617-573-3698
Place of Birth:
Taipei, Taiwan (Citizenship: United States)
Education
08/1974–08/1977
B.S.
(with distinction)
Molecular Biology
University of Wisconsin–Madison
08/1977–12/1980
M.D.
Medicine
University of Wisconsin–Madison
01/1981–06/1982
M.A.
Biology
Harvard University
07/1982–06/1984
Ph.D.
Biology (advisor:
John E. Dowling)
Harvard University
07/1984–06/1985
Transitional Intern
Medicine
Framingham Union Hospital,
Framingham, MA
07/1985–06/1988
Resident
Ophthalmology
Harvard Medical School,
Massachusetts Eye and Ear Infirmary
07/1988–06/1990
Clinical and
Research Fellow
Ophthalmology—
Vitreoretinal
Disease
Massachusetts Eye and Ear Infirmary
Postdoctoral Training
Faculty Academic Appointments
07/1987–06/1992
Research Associate
Harvard University
07/1989–12/1992
Instructor in Ophthalmology
Harvard Medical School
10/1992–12/1997
Assistant Professor of Ophthalmology
Harvard Medical School
01/1998–
Associate Professor of Ophthalmology
Harvard Medical School
Appointments at Hospitals/Affiliated Institutions
09/1989–01/1993
Assistant in Ophthalmology
Massachusetts Eye and Ear Infirmary
01/1993–01/1996
Assistant Surgeon, Ophthalmology
Massachusetts Eye and Ear Infirmary
01/1996–01/2004
Associate Surgeon, Ophthalmology
Massachusetts Eye and Ear Infirmary
07/1996–
Clinical Associate in Surgery
Massachusetts General Hospital
01/2004–
Surgeon, Ophthalmology
Massachusetts Eye and Ear Infirmary
06/2009–
Associate Surgeon to the Affiliate Staff
Brigham and Women’s Hospital
Other Professional Positions
2013–
Scientific Advisory Board
Biosyntrx Nutritional Biotechnology
Major Administrative Leadership Positions
Local
2004–
Board of Surgeons
Massachusetts Eye and Ear Infirmary
2011–2013
President of Eye Staff
Massachusetts Eye and Ear Infirmary
2011–2012
President-Elect of Medical Staff
Massachusetts Eye and Ear Infirmary
2011–2015
Physician Director to the Massachusetts
Eye and Ear Associates Board
Massachusetts Eye and Ear Infirmary
2012–2013
President of Medical Staff
Massachusetts Eye and Ear Infirmary
Course coordinator (Retina Section)
Lancaster Course in Ophthalmology
Colby College, Waterville, Maine
2001
Course Director, Advances in Retina
Diseases
Kevin Hill Seminar in Ophthalmology
Colby College, Waterville, Maine
2002–
Director
Lancaster Course in Ophthalmology
Colby College, Waterville, Maine
2002–
Organizer and Co-Moderator
Fluorescein Angiography Conference
The Retina Society
Regional
1991–
National and International
2002–
Co-Moderator, Program Organizer
Fluorescein Angiography Conference
The Retina Society
Utilization Review Committee
2004–
Massachusetts Eye and Ear Infirmary
Chairperson
Committee Service
Local
1990–
1990–2004
Pharmacy and Therapeutics Committee
Massachusetts Eye and Ear Infirmary
1994–
Specialty Advisors Committee
Massachusetts Eye and Ear Infirmary
1996–2008
Continuing Quality Improvement
Committee
Massachusetts Eye and Ear Infirmary
1999–2009
Scientific Center Utilization Review
Committee
Massachusetts Eye and Ear Infirmary
2000–
Joint OR Committee
Massachusetts Eye and Ear Infirmary
2000–2004
Medical Records Committee
Massachusetts Eye and Ear Infirmary
2002
Joint Commission on Accreditation of
Healthcare Organizations Medical Staff
Leadership Committee
Massachusetts Eye and Ear Infirmary
2002–2004
Infectious Disease Control Committee
Massachusetts Eye and Ear Infirmary
2002–2009
Eye Service Executive Committee
Massachusetts Eye and Ear Infirmary
2003
Member, Chief of Anesthesia Search
Committee
Massachusetts Eye and Ear Infirmary
2003
Smallpox Subcommittee
Massachusetts Eye and Ear Infirmary
2005
Member, Director of the Uveitis Service
Search Committee
Massachusetts Eye and Ear Infirmary
2011
Member, AMD Center of Excellence
Interest Group
Schepens Eye Research Institute,
Massachusetts Eye and Ear Infirmary
2012–
Retina First Assist Program Task Force
Massachusetts Eye and Ear Infirmary
National and International
1998–2000
Research Committee
The Macula Society
2007–
Research Award Selection Committee
The Retina Society
2009–
Fellowship Research Award Selection
Committee
The Retina Society
Professional Societies
1982–
Association for Research in Vision and Ophthalmology
1984–
Society for Neuroscience
1988–
Massachusetts Eye and Ear Infirmary Alumni Association
1989–
American Academy of Ophthalmology
1990–
Massachusetts Society of Eye Physicians and Surgeons
1994–
The Retina Society
2007–present: The Fellowship Research and Raymond R. Margherio Award
Selection Committee
1995–
The New England Ophthalmological Society
1995–
American College of Surgeons
1996–
The Macula Society
2002–
Club Jules Gonin
Editorial Activities
Ad Hoc Reviewer
Ophthalmology
Archives of Ophthalmology
American Journal of Ophthalmology
Retina
Middle East Journal of Ophthalmology
Ophthalmic Surgery Lasers & Imaging
Honors and Prizes
1974–1977
Epsilon Sigma Epsilon
Chancellor’s Vilas Scholarship
Letters and Science Honors Program
Dean’s List, graduated with distinction
University of Wisconsin–Madison
1981–1984
Springer Verlag Scholarship
(NIH Training Fellowship)
National Institutes of Health
1988–1989
Heed Fellowship
Heed Foundation
1988–1990
National Research Service Award
National Institutes of Health
1989–1990
Heed Foundation/Knapp Fellowship
AOS-Knapp Fund
1998
Teaching Award
Lancaster Course in Ophthalmology
1998
Nominee, A. Clifford Barger Award for
Excellence in Mentoring
Harvard Medical School
2004
Nominee, A. Clifford Barger Award for
Excellence in Mentoring
Harvard Medical School
2004
Distinguished Service Award
Massachusetts Eye and Ear Infirmary
2005
Nominee, A. Clifford Barger Award for
Excellence in Mentoring
Harvard Medical School
2006
Nominee, A. Clifford Barger Award for
Excellence in Mentoring
Harvard Medical School
2011
First Annual Vitreoretinal Fellowship
Teaching Award
Massachusetts Eye and Ear Infirmary
REPORT OF FUNDED PROJECTS
Funding Information
1988–1989
Retina-specific antigens and their potential for inducing uveitis-like disorders
NIH - DRR Biomedical Research Support Group
Co-I ($5,000)
1989–1990
Immunoregulation of ocular malignant melanoma in an experimental animal model
Fight for Sight
PI ($11,000)
1989
Immunoregulation of ocular malignant melanoma in an experimental animal model
NIH - DRR Biomedical Research Support Group
Co-I ($14,122)
1990–1991
Molecular basis of cell-mediated tumor cell killing: characterization of cytotoxic mediators
involved in situ
NIH–DRR Biomedical Research Support Group
Co-I ($5,000)
1990–1991
Immunoregulation of intraocular inflammatory disorders
Research to Prevent Blindness
PI ($15,000)
1990–1995
Endophthalmitis vitrectomy study
National Eye Institute
Collaborator
To determine the role of initial pars plana vitrectomy in the management of postoperative
bacterial endophthalmitis; to determine the role of intravenous antibiotics in the
management of bacterial endophthalmitis; to determine which factors, other than treatment,
predict outcome in postoperative bacterial endophthalmitis.
1991
Immunoregulation of ocular melanoma in an experimental animal model: characterization
of cytotoxic mediators
Elsa U. Pardee Foundation
PI ($23,055)
1991–1992
Immunoregulation of ocular melanoma: characterization of cytotoxic mediators
Mass Lions Fund
PI ($10,000)
1992
Immunoregulation of ocular melanoma in an experimental animal model: characterization
of cytotoxic mediators
Elsa U. Pardee Foundation
PI ($23,830)
1992
Photoimmunotherapy of ocular melanoma
Department of Energy Fellowship
PI ($16,000)
1992–1994
MGH Fellowship Fund
PI ($31,727)
1993–1994
Immunoregulation of ocular melanoma: characterization of cytotoxic mediators
Mass. Lions Fund
PI ($7,398)
1993
Immunoregulation of ocular malignant melanoma in an experimental animal model
Milton Fund
PI ($6,000)
1993
Unrestricted Research
Patient Donations
PI ($1,000)
1993–1994
Animal model of retinal toxicity
Regeneron Pharma
PI ($685)
1993–1994
Immunoregulation of ocular melanoma: characterization of cytotoxic mediators
Mass Lions Award
PI ($5,370)
1994
Photodynamic therapy of ocular melanoma
Research to Prevent Blindness
PI ($12,500)
1994–1995
Immunoregulation of ocular melanoma: characterization of cytotoxic mediators
Mass. Lions Fund
PI ($7,398)
1994–1999
Ocular melanoma: development of a photodynamic therapy
NIH-NEI 1R29EY10975
PI ($589,799)
1995–1996
Immunoregulation of ocular melanoma: characterization of cytotoxic mediators
Mass. Lions Fund
PI ($6,649)
1996–1997
Photodynamic therapy of ocular melanoma via a trans-scleral approach
Mass. Lions Fund
PI ($7,952)
1997–1998
Dynamic magnetic resonance imaging of choroidal melanoma following photodynamic
therapy
Mass. Lions Fund
PI ($7,718)
1997
Photodynamic therapy for the treatment of ocular melanoma
Charitable Trust Fund
PI ($25,000)
1998–1999
Photodynamic therapy of choroidal melanoma using a near-infrared photosensitizer
Mass. Lions Fund
PI ($6,813)
1998
Photodynamic therapy for the treatment of ocular melanoma
Charitable Trust Fund
PI ($25,000)
1998–2002
Evaluation of multi-photon excitation (MPE) of endogenous chemical compounds for the
treatment of ocular melanoma
Photogen Tech
PI ($190,000)
1999–2000
Destruction of choroidal melanoma using two-photon photodynamic therapy
Mass. Lions Fund
PI ($8,333)
1999
Photodynamic therapy for the treatment of ocular melanoma
Charitable Trust Fund
PI ($25,000)
2000–2001
Photodynamic therapy of choroidal melanomas by multiphoton excitation of melanin
precursors
Mass. Lions Fund
PI ($7,684)
2000
Photodynamic therapy for the treatment of ocular melanoma
Charitable Trust Fund
PI ($25,000)
2001
Photodynamic therapy for ocular melanoma
Bacardi Research Fund
PI ($10,700)
2001–2002
Thermotherapy of choroidal melanoma using a Nd:YLF-Laser at 1047nm
Mass. Lions Fund
PI ($9,133)
2001
Photodynamic therapy for the treatment of ocular melanoma
Charitable Trust Fund - $25,000
2001–2003
Dexamethasone clinical trial
Oculex Pharma
PI ($110,284)
Phase II multicenter trial to assess the safety and efficacy of dexamethasone posterior
segment drug delivery system in the treatment of persistent macular edema
2001–2004
Parexel protein kinase C-diabetic retinopathy study 2 (PKC-DRS2)
Parexel Int'l Corp / Eli Lilly B7A-MC-MBCM
PI ($29,572)
Multicenter, randomized study to evaluate oral administration of ruboxistaurin, an orally
active protein kinase C beta (PKC beta) inhibitor, using optical coherence tomography over
a period of 18 months
2002–2003
Destruction of choroidal melanoma with transpupillary thermotherapy 1047nm Nd:YLF
laser vs. 810 nm diode laser
Mass. Lions Fund
PI ($11,399)
2002
Photodynamic therapy for the treatment of ocular melanoma
Charitable Trust Fund
PI ($25,000)
2003–2004
Detection of tumor-related cytokines in the sera of patients with ocular melanoma
Mass. Lions Fund
PI ($11,500)
2003
Photodynamic therapy for the treatment of ocular melanoma
Charitable Trust Fund
PI ($25,000)
2003–2005
Phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative
trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal
injections of EYE001 (anti-VEGF pegylated aptamer), given every 6 weeks for 12 to 30
weeks to patients with clinically significant diabetic macular edema (CSME ) involving the
center of the macula
Eyetech Pharma EOP1005
Co-I ($14,980)
The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and
effective in slowing the leakage of fluid within the retina and thereby stabilizing or
improving vision when compared to placebo injections.
2004–2005
The role of angiogenesis in ocular melanoma
Mass. Lions Fund
PI ($14,184)
2004
Photodynamic therapy for the treatment of ocular melanoma
Charitable Trust Fund
PI ($25,000)
2004
Development of an alternative therapy for ocular melanoma
Bacardi Cancer Research Fund
PI ($18,341)
2004
Development of an alternative therapy for the management of ocular melanoma
S. Elizabeth O’Brien Trust
PI ($60,000)
2004–2006
Pegaptanib sodium compared to sham injection in patients with recent vision loss due to
macular edema secondary to central retinal vein occlusion (CRVO)
Eyetech Pharma EOP1011
Co-I ($61,400)
Phase II multicenter trial to determine the safety, efficacy and pharmacokinetics of
intravitreous injections of Macugen compared to sham injection in patients with macular
edema secondary to central retinal vein occlusion
2005
Photodynamic therapy for the treatment of ocular melanoma
Charitable Trust Fund
PI ($25,000)
2005–2006
Search for angiogenesis inhibitors for ocular melanoma
Mass. Lions Fund
PI ($14,098)
2005
Unrestricted Research
Patient Donation
PI ($2,500)
2005–2008
A Phase I trial of siRNA-027
Sirna Therapeutics SIRNA 0401
PI ($72,607)
Phase I multicenter trial to establish safety and efficacy of a single intravitreal injection of
SIRNA
2005–2009
Intravitreal dexamethasone PS DDS vs. sham in patients with central or branch retinal vein
occlusion
Allergan 206207-009
PI ($65,954)
Phase 3 multicenter trial to assess the safety and efficacy of dexamethasone posterior
segment drug delivery system (Posurdex) in the treatment of patients with macular edema
secondary to branch and central retinal vein occlusion
2005–2012
Dexamethasone PS DDS vs. sham in patients with diabetic macular edema
Allergan 206207-011
PI ($95,110)
Phase 3 multicenter trial to assess the safety and efficacy of dexamethasone posterior
segment drug delivery system (Posurdex) in the treatment of patients with diabetic macular
edema
2006–2007
Search for anti-interferon antibodies in patients treated with adjunctive interferon therapy
after proton beam irradiation for ocular melanoma
Mass. Lions Fund
PI ($14,000)
2006
Phase 3B multicenter trial to compare the safety and efficacy of intravitreal injections of
Macugen to PDT with visudyne in patients with exudative age related macular degeneration
Eyetech EOP1012
Co-I
To compare whether Macugen (pegaptanib sodium) in combination with PDT with
Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the
eye and thereby stabilizing or improving vision when compared to Macugen alone. Patients
must be recently diagnosed with predominantly classic wet AMD and must be eligible for
PDT.
2006
Photodynamic therapy for the treatment of ocular melanoma
Charitable Trust Fund
PI ($30,000)
2006–2009
Protein kinase C (PKC) inhibitor-diabetic retinopathy Phase 3 study
Lilly Research Labs
PI ($7790)
Phase 3 multicenter trial to assess the safety and efficacy of ruboxistaurin, a protein kinase
C inhibitor, in preventing or reducing the progression of proliferative diabetic retinopathy
2006–2012
Age-related eye disease study 2 (AREDS2 )
Co-I ($254,689)
NEI
Phase 3 multicenter trial to investigate the effects of oral supplements of lutein/zeaxanthin
and omega-3 fatty acids for the treatment of AMD
2007
Photodynamic therapy for the treatment of ocular melanoma
Charitable Trust Fund
PI ($30,000)
2007–2008
Investigation of Inhibition of AMP-activated kinase as a novel treatment for choroidal
neovascularization in rats
Mass. Lions Fund
PI ($9,623)
2007–2008
Phase 3 multicenter trial to evaluate efficacy and safety of posterior juxtascleral
administration of anecortave acetate for depot suspension vs. sham administration in
patients at risk for developing sight threatening CNVM due to exudative AMD
Alcon
Co-I
To evaluate anecortave acetate compared to placebo for maintenance of visual acuity after
24 months of treatment in patients with subfoveal choroidal neovascularization (CNV) due
to exudative age-related macular degeneration (AMD).
2007–2010
Ranibizumab versus sham in patients with branch retinal vein occlusion (BRAVO)
Genentech FVF4165g
PI ($440,000)
Phase 3 multicenter trial to study the efficacy and safety of Lucentis for branch retinal vein
occlusion (BRAVO)
2007–2010
Phase 3 multicenter trial to evaluate efficacy and safety of Lucentis for central retinal vein
occlusion (CRUISE)
Genentech
PI ($440,000)
2008–2009
Investigation of inhibition of AMP-activated kinase as a novel treatment for choroidal
neovascularization in macular degeneration
Mass Lions Fund
PI ($9,451)
2008
Toxoplasmic retinitis basic biology
Charitable Trust Fund
PI ($30,000)
2009–2010
Investigation of the role of Fas/FasL interactions in the pathogenesis of age related macular
degeneration
Mass Lions Fund
PI ($9,198)
2009
Toxoplasmic retinitis basic biology
Charitable Trust Fund
PI ($30,000)
2009–2010
Intravitreal ranibizumab extension study for patients who have completed a Genentech
ranibizumab trial (HORIZON)
Genentech FVF3426g
PI ($17,530)
An open-label, multicenter extension study to evaluate the safety and tolerability of
ranibizumab in subjects with choroidal neovascularization (CNV) secondary to age-related
macular degeneration (AMD) or macular edema secondary to retinal vein occlusion (RVO)
who have completed a Genentech-sponsored ranibizumab study
2010
Mass Lions Fund
PI ($9,531)
2010
Toxoplasmic retinitis basic biology
Charitable Trust Fund
PI ($30,000)
2011
Toxoplasmic retinitis basic biology
Charitable Trust Fund
PI ($30,000)
2011
Unrestricted research
Patient Donation
PI ($2,500)
2012
Unrestricted research
Patient Donation
PI ($2,500)
2012–2013
Toxoplasmic retinitis basic biology
Charitable Trust Fund
PI ($35,000)
2012–2013
Serotyping toxoplasma infections: correlating strain genotype to severity of infection
Massachusetts Lions Fund
PI ($25,000)
2008–2013
Phase 3, double-masked, multicenter trial to evaluate the efficacy and safety of
Ranibizumab injection in subjects with clinically significant macular edema with center
involvement secondary to diabetes mellitus (RISE)
Genentech FVF4168g
Co-I ($206,293)
2013
Unrestricted research
Patient Donation
PI ($2,500)
2013
Unrestricted research
Patient Donation
PI ($2,500)
2012–
Comparison of anti-vascular endothelial growth factors agents in the treatment of macular
edema following retinal vein occlusion (CRAVE)
Genentech
Collaborator
A six-month randomized, prospective interventional trial comparing the effectiveness of
ranibizumab with bevacizumab in the treatment of macular edema from RVO.
2012–
A Phase I/IIa, open-label, single-center, prospective study to determine the safety and
tolerability of sub-retinal transplantation of human embryonic stem cell derived retinal
pigmented epithelial (MA09-hRPE) cells in patients with advanced dry age-related macular
degeneration (AMD)
Advanced Cell Technology
Collaborator
To evaluate the safety and tolerability of MA09-hRPE cellular therapy in patients with
advanced dry AMD; to evaluate the safety of the surgical procedures when used to implant
MA09-hRPE cells; to assess the number of hRPE cells to be transplanted in future studies
To evaluate on an exploratory basis potential efficacy endpoints to be used in future studies
of MA09-hRPE cellular therapy.
2012–
A randomized, multi-center, Phase II study of the safety, tolerability and bioactivity of
repeated intravitreal injections of iCo-007 as monotherapy or in combination with
ranibizumab or laser photocoagulation in the treatment of diabetic macular edema (the
iDEAL Study)
Juvenile Diabetes Research Foundation; iCo Therapeutics Inc.
Collaborator
To assess the safety of repeated iCo-007 intravitreal injections in treatment of subjects with
diabetic macular edema as monotherapy and in combination with ranibizumab or laser
photocoagulation. To assess the change in visual acuity and retinal thickness on OCT from
baseline to month 8 and month 12
2013–
Safety and efficacy assessment treatment trials of emixustat hydrochloride (SEATTLE)
Acucela 4429-202
Co-I
A Phase 2b/3 multicenter, randomized, double-masked, dose-ranging study comparing the
efficacy and safety of emixustat hydrochloride (ACU-4429) with placebo for the treatment
of geographic atrophy associated with dry age-related macular degeneration
2014
Unrestricted research
Patient Donation
PI ($2,500)
2014
Unrestricted research
Patient Donation
PI ($2,500)
2014
Toxoplasmic retinitis basic biology
Charitable Trust Fund
PI ($35,000)
REPORT OF LOCAL TEACHING AND TRAINING
Teaching of Students in Courses
1981
Neurobiology
(undergraduate students)
Harvard University
Teaching Fellow, one-semester course
1981
Immunology
(undergraduate students)
Harvard University
Teaching Fellow, one-semester course
1991–
OP501M.8 Ophthalmology
(3–4 medical students per year)
Harvard Medical School
Instructor, 4-week elective course
2003–
MR700.0 Mentored Clinical
Casebook Project
(medical students)
Harvard Medical School
Specialist Consultant Mentor, 9-month clinical elective
course
2005
Ophthalmology for the Internist
(medical students)
Harvard Medical School 6th Annual Partners Physicians
Day, one-day course (2/12/05), three lectures
2008–
IN761 Patient Doctor II
(medical students)
Harvard Medical School
Instructor, one-semester course
2008–
HST 160 Molecular Biology and
Genetics in Modern Medicine
(2–4 medical students per year)
Harvard Medical School
Instructor, one-semester course
Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)
1990–
Instructor, Lancaster Course in
Ophthalmology
(national and international
residents, clinical fellows, and
practicing ophthalmologists; 4050 students per summer)
Massachusetts Eye and Ear Infirmary, Harvard Medical
School/Colby College, Waterville, Maine
Teach courses in 7-week program (12+ lectures
annually). Topics include: Diabetic Retinopathy;
Miscellaneous Maculopathies; Management of Retinal
Detachment; Infectious Retinopathies; Challenging
Inflammatory/Infectious Cases; Clinical Case
Presentations with Audience Participation; Fluorescein
Angiography Lab (3-hour session, twice per course);
Peripheral Retina Anatomy/Pathology; Vitreous
Surgery; Echography; Uveitis Syndromes; Hereditary
Macular Diseases; Hereditary Optic Disc Anomalies
2010, 2011, Instructor, Annual Mass. Eye
2013, 2014 and Ear Vitreoretinal Course
(first-year retina fellows)
Massachusetts Eye and Ear Infirmary
2013–
Massachusetts Eye and Ear Infirmary
Generate didactic schedule; assist the residency program
in generating appropriate documentation for the rotation
(defining goals, objectives, assessment methods, etc.);
and meet with the Accreditation Council for Graduate
Medical Education (ACGME) site visitor
Curriculum Advisor,
Subspecialty Service (Retina)
Clinical Supervisory and Training Responsibilities
1989–
Retina Service Attending
Massachusetts Eye and Ear Infirmary, Harvard Medical
(4-6 medical students; 8 junior, 8 School
intermediate, and 8 senior
residents; 6 clinical fellows; and
2-4 foreign visiting physicians;
per year)
Laboratory and Other Research Supervisory and Training Responsibilities
1981–1994
Undergraduate Thesis Advisor,
Harvard University
Daily supervision and advising for undergraduate
Biology Honors thesis students
1989–
Retina Service Attending
(1-2 research fellows per year)
Massachusetts Eye and Ear Infirmary, Harvard Medical
School
1990–
Principal Investigator,
Massachusetts Eye and Ear
Infirmary
Oversee research program with 1-3 research
fellows/year; acquire funds to cover supply and salary
expenses; oversee finances; design experiments and
oversee fellows’ progress; prepare manuscripts for
publication.
Formally Supervised Trainees
1983–1985
Yan Min Wang
Undergraduate biology honors thesis student; daily supervision and advising
1986–1988
Nancy Benegas, MD / Assistant Professor of Ophthalmology, Vanderbilt University School
of Medicine; Pediatric Ophthalmology, Vanderbilt Eye Institute
Undergraduate biology honors thesis student; daily supervision and advising
1990–1992
Abraham Chyung, MD, PhD / Private practice (neurology), La Jolla, CA
Undergraduate biology honors thesis student; daily supervision and advising
1990–1992
David Guyer, MD / CEO, Ophthotech; Venture Partner, SV Life Sciences Venture Capital;
Chairman of the Board, Lux Biosciences, NeoVista, Neurotech, and Panoptica; former CEO
and co-founder, Eyetech
Clinical fellow
1991–1993
Arthur Walsh, MD / Private Practice, Lebanon, NH
Clinical fellow
1991–1993
Mark Balles, MD / Private Practice, South Portland, ME
Clinical fellow
1991–1993
Kuhl Huh, MD / Private practice, Korea
Research fellow
Published 1 peer-reviewed original research article
1991–1993
Monica de la Paz, MD / Private practice, TX
Research and clinical fellow
Published one peer-reviewed review article
1991–1996
Li-Kuan Hu, MD / Director of Radiation Oncology, Shandong Medical School, Shandong,
China
Research fellow
Published 8 peer-reviewed original research articles
1992–1993
Andrea da Mata, MD / Private practice, Loveland, OH
Research fellow
1992–1994
Robert Haimovici, MD / Deceased; formerly Assistant Professor of Ophthalmology, Boston
University School of Medicine
Clinical fellow
1993–1994
Victor Gonzales, MD / Private practice, McAllen, TX
Research and clinical fellow
Published one peer-reviewed original research article
1993–1994
Marcie Howard, MD / Private practice, McAllen, TX
Research and clinical fellow
Published 1 peer-reviewed original research article
1994–1996
Gary Haynie, MD / Private practice, Fargo, ND
Research and clinical fellow
Published 2 peer-reviewed original research articles
1994–1996
David Weissgold, MD / Private practice, Burlington, VT
Research and clinical fellow
1994–1996
Bradley Foster, MD / Private practice, Springfield, MA
Research and clinical fellow
Published 1 peer-reviewed original research article, 1 peer-reviewed review article
1994–1996
Susanna Park, MD, PhD / Associate Professor in Ophthalmology, University of California–
San Diego
Research and clinical fellow
Published 1 peer-reviewed original research article
1994–1996
William Stinson, MD / Private Practice, Beverly, MA
Clinical fellow
1994–1996, Chandler Samiy, MD / Private practice, Ocala, FL
Clinical fellow
1995–1997
Martin Reinke, MD / Private practice, Dallas TX
Clinical fellow
1996–1998
James Palmer, MD / Private Practice, Mountain View, CA
Clinical fellow
1996–1998
Robert Bhisitkul, MD, PhD / Professor of Clinical Ophthalmology, University of California
San Francisco
Clinical fellow
1996–1998
Panos G. Theodossiadis, MD / Associate Professor of Ophthalmology, University of Athens
Medical School, Greece
Research fellow
Published 2 peer-reviewed original research articles
1997
Roberto Pineda, MD / Associate Professor of Ophthalmology, Harvard Medical School;
Director, Keratorefractive Surgery Service, Massachusetts Eye and Ear Infirmary
Research fellow and resident
Published 1 peer-reviewed original research article
1997
Tueng T. Shen, MD, PhD / Associate Professor of Ophthalmology and adjunct in
Bioengineering, University of Washington School of Medicine, Seattle, WA
Medical Student
Published 1 peer-reviewed original research article
1997–1999
Jean Daniel Arbour, MD / Professor of Ophthalmology and Chair, Department of
Ophthalmology, University of Montreal
Clinical fellow
1997–1999
Timothy You, MD / Private practice, Orange County, California
Clinical fellow
Published 1 peer-reviewed review article
1998–2000
Kenneth Graham, MD / Private practice, Long Island, NY
Clinical fellow
1998–2000
Mathias Krause, MD / Faculty, University of Saarland, Homburg, Germany
Research fellow
Published 4 peer-reviewed original research articles
1998–2000
Magda Krzystolik, MD / Private practice, RI and MA
Clinical fellow
Published 1 peer-reviewed original research article
1995–2000
Rosa Kim, MD / Private practice, Houston, TX
Research and clinical fellow
Published 3 peer-reviewed original research articles, 2 peer-reviewed review articles, and 2
book chapters
1998–2000
Jay Ambati, MD / Professor of Physiology and Professor & Vice-Chair of Ophthalmology
and Visual Sciences, University of Kentucky
Clinical fellow
1999–2001
Danny Gauthier, MD / Clinical Professor of Ophthalmology, University of Montreal
Clinical Fellow
1999–2001
Ron Afshari, MD, MPH, MBA, FACS / Professor of Ophthalmology & Visual Science;
Director of the Retina Service, Yale University School of Medicine
Clinical fellow
2000–2002
Eugene Lit, MD / Private practice, CA
Clinical fellow
Published 1 peer-reviewed review article
1999–2002
Ayman Youssri, MD / Private practice, Washington, DC
Clinical fellow
Published 1 peer-reviewed review article
2000–2002
David N. Zacks, MD, PhD / Associate Professor of Ophthalmology, University of
Michigan, Ann Arbor, Michigan
Clinical fellow
Published 1 peer-reviewed case report, 1 peer-reviewed review article
2001–2003
Deeba Husain, MD / Lecturer on Ophthalmology, Harvard Medical School; Mass. Eye and
Ear Retina Consultants
Clinical fellow
2001–2003
Ivana Kim, MD / Associate Professor of Ophthalmology, Harvard Medical School; CoDirector, Macular Degeneration Unit, Mass Eye & Ear Infirmary
Clinical fellow
2001–2003
Subhransu Ray, MD, PhD / Private practice, San Francisco, CA
Clinical fellow
Published 1 peer-reviewed case report
2002–2004
Atul Sharma, MD / Private practice, Atlanta, GA
Clinical fellow
2002–2004
Sean Koh, MD / Private practice, Atlanta, GA
Clinical fellow
2002–2004
Tara Young, MD / Assistant Professor in Ophthalmology, University of California–LA
Clinical fellow
2003–2005
Jennifer K. Sun, MD, MPH / Assistant Professor of Ophthalmology, Harvard Medical
School, Beetham Eye Institute, Joslin Diabetes Center
Clinical fellow
Published 1 book chapter in Albert & Jakobiec's Principles and Practice of Ophthalmology
2003–2005
Lucia Sobrin, MD, MPH / Assistant Professor of Ophthalmology, Harvard Medical School;
Director, Morse Laser Center, Massachusetts Eye and Ear Infirmary
Clinical fellow
2003–2005
John Christoforidis, MD / Associate Professor of Ophthalmology, University of Arizona
College of Medicine
Clinical fellow
2002–2005
F. Max Damico, MD / Assistant Professor of Ophthalmology, Universidade de Sao Paulo
Medical School, Sao Paulo, SP, Brazil
Research fellow
Published 1 peer-reviewed original research article, 3 peer-reviewed review articles, 2
review articles, 1 book chapter
2004–2006
Nadia Waheed, MD / Assistant Professor of Ophthalmology, Tufts University School of
Medicine, Boston, MA
Clinical fellow
Published 1 peer-reviewed review article, 1 book chapter in in Albert & Jakobiec's
Principles and Practice of Ophthalmology
2004–2006
Janie Ho, MD / Private practice, Beverly, MA
Clinical fellow
2004–2006
R.V. Paul Chan, MD / Associate Professor of Ophthalmology, Weill - Cornell Medical
College, NY, New York
Clinical fellow
Published 1 peer-reviewed review article
2005–2007
Susie Chang, MD / Assistant Professor of Ophthalmology, The Ohio State University
Medical Center, Columbus, Ohio
Clinical fellow
Published 1 peer-reviewed review article
2005–2007
Fina Barouch, MD / Assistant Clinical Professor of Ophthalmology, Tufts School of
Medicine, Boston, MA
Clinical fellow
2005–2007
Demetrios Vavvas, MD / Assistant Professor of Ophthalmology, Harvard Medical School;
Massachusetts Eye and Ear Infirmary
Clinical fellow
Published 2 peer-reviewed original research articles (as collaborator), 3 meeting abstracts
(as collaborator)
2006–2007
Christopher Andreoli, MD / Staff physician, Harvard Vanguard, Boston, MA
Clinical fellow
2006–2007
Szilard Kiss, MD / Assistant Professor of Ophthalmology, Weill - Cornell Medical College,
New York, NY
Clinical fellow
Published 3 peer-reviewed review articles, 1 review article
2008–2009
Vasiliki Poulaki, MD / Assistant Professor of Ophthalmology, Boston VA
Boston, MA
Clinical fellow
2008–2009
Corey Westerfeld, MD / Private Practice, MA
Clinical fellow
2008–2009
Daniel Esmaili, MD / Private practice, Los Angeles, CA
Clinical fellow
2008–2010
Cynthia Cordeiro, MD, PhD / Assistant Professor of Ophthalmology, Centro Brasileiro de
Ciências Visuais, Belo Horizonte, MG, Brazil
Research Fellow
Published 3 peer-reviewed original research articles, 1 peer-reviewed review,7 meeting
abstracts
2009–2011
Netan Choudhry, MD, FRCS(C) / Director of Vitreoretinal Surgery, Herzig Eye Institute,
Toronto, ON
Clinical fellow
2009–2011
Marc-Andre Rheaume, MD / Assistant Professor of Ophthalmology, University of
Montreal, Canada
Clinical fellow
Published 1 meeting abstract
2009–2011
Babak Jian, MD / Private practice, MA
Clinical fellow
2007–2011
Aristomenis Thanos, MD / Resident, Harvard Medical School Ophthalmology Residency
Program, Massachusetts Eye and Ear Infirmary
Research fellow
Published 2 peer-reviewed original research articles, 1 peer-reviewed case report, 3 meeting
abstracts
2008–2011
Sahar Kohanim, MD / Assistant Professor of Ophthalmology & Visual Sciences, Vanderbilt
University Medical Center
Ophthalmology Resident and Clinical Fellow
Published 2 peer-reviewed review articles
2009–2012
Miriam Englander, MD / Vitreoretinal Fellow, Cole Eye Institute, Cleveland Clinic,
Cleveland OH
Ophthalmology Resident
Published 1 peer-reviewed review article
2009–2012
Nancy Huynh, MD / Ophthalmic Genetics Fellow, National Eye Institute
Ophthalmology Resident
Published 2 peer-reviewed review articles
2010–2012
Jason Comander, MD, PhD / Instructor in Ophthalmology, Harvard Medical School
Clinical fellow
2010–2012
Yevgeniy (Eugene) Shildkrot, MD / Assistant Professor of Ophthalmology, University of
Virginia Health System, Charlottesville, Virginia
Clinical fellow
2010–2012
Grace Chang, MD, PhD / Assistant professor, University of Washington, Seattle, WA
Clinical fellow
Published 1 peer-reviewed review article
2011–2012
Murilo Abud, MD / Private practice, Goiania, Brazil; Retina Fellowship Preceptor, Federal
University of Goias, Goiania, Brazil and Federal University of Triangulo Mineiro, Uberaba,
Brazil
Research fellow
2011–2013
Dimitra Skondra, MD / Assistant Professor of Ophthalmology, Northwestern University;
Vitreoretinal Attending/Director of Vitreoretinal Surgery, J. Stroger Cook County Hospital
Clinical fellow
2011–2013
Anthony Daniels, MD / Assistant Professor of Ophthalmology and Visual Science,
Vanderbilt Eye Institute, Vanderbilt University
Clinical fellow
Published 2 peer-reviewed review articles
2012–
Harpal Sandu, MD
Ophthalmology Resident
Published 1 peer-reviewed review article
2013
Marion Hsueh
MS Candidate in Biomedical Sciences, Tufts University School of Medicine
Formal Teaching of Peers (e.g., CME and other continuing education courses)
1990–
Instructor, Lancaster Course in
Ophthalmology
(national and international
residents, clinical fellows, and
practicing ophthalmologists; 4050 students per summer)
Massachusetts Eye and Ear Infirmary, Harvard Medical
School/Colby College, Waterville, Maine
Teach courses in 7-week program (12+ lectures
annually)
2005
HIV-associated retinal infections
MGH HOPE (HIV-Online
Provider Education to South
Africa)
Single presentation
Online
Local Invited Presentations
1993
Photoimmunotherapy of ocular melanoma / Invited Lecture
Massachusetts General Hospital
1994, 1995
Practical Ophthalmology for Primary Care / Invited Lecture
Massachusetts Eye and Ear Infirmary
1994
Retina Workshop for Nurses and Technicians / Invited Lecture
Massachusetts Eye and Ear Infirmary
1998
Nursing Education: Update on Diabetic Retinopathy / Invited Lecture
Massachusetts Eye and Ear Infirmary
1998
Vision Rehabilitation Lecture Series / Invited Lecture
Massachusetts Eye and Ear Infirmary
1998
Endocrine Seminar Series: Management of Diabetic Retinopathy / Invited Lecture
Massachusetts General Hospital
1998–
Boards Review: Miscellaneous Macular Diseases / Invited Lecture
Massachusetts Eye and Ear Infirmary
1998–
Boards Review: Infectious Retinitis / Invited Lecture
Massachusetts Eye and Ear Infirmary
1998–
Boards Review: Retinal Vascular Diseases / Invited Lecture
Massachusetts Eye and Ear Infirmary
1999, 2000
Intensive Review of Ophthalmology Course / Invited Lecture
Harvard Medical School, Cambridge, MA
2000
Retina Overview / Invited Lecture
Nursing Education, Massachusetts Eye and Ear Infirmary
2000
Retina Overview for Surgical Technicians / Invited Lecture
Massachusetts Eye and Ear Infirmary
2001
Posterior segment inflammatory disorders / Invited Lecture
Schepens Eye Research Institute
2002
Endocrine Seminar Series: Management of Diabetic Retinopathy / Invited Lecture
Massachusetts General Hospital
2002
Infectious Disease Seminar Series: AIDS Retinopathy / Invited Lecture
Massachusetts General Hospital
2003
Endocrine Seminar Series: Diabetic Retinopathy–Every Year / Invited Lecture
Massachusetts General Hospital
2003
Infectious Retinitis / Invited Lecture
Massachusetts Eye and Ear Infirmary
2003
Infectious Retinitis: Clinical case presentations / Invited Lecture
Massachusetts Eye and Ear Infirmary
2004
Management of Diabetic Retinopathy / Invited Lecture
Massachusetts Eye and Ear Infirmary
2005
HIV-associated retinal infections / Invited Lecture
Massachusetts General Hospital–HIV Conference
2005
HIV-associated retinal infections / Invited Lecture
Massachusetts General Hospital / MGH HOPE (HIV-Online Provider Education to South
Africa)
2005
Infectious Retinitis / Invited Lecture
Update on Ophthalmology, Massachusetts Eye and Ear Infirmary
2005
Ophthalmology For The Internist: Retinal Vascular Diseases (Diabetic Retinopathy;
Arterial and Vascular Occlusions; Carotid Artery Disease; Radiation Retinopathy) / Invited
Lecture
6TH Annual Partners Physicians Day
2005
Ophthalmology For The Internist: Age-related macular degeneration (Dry; Wet – laser,
photodynamic therapy, surgery and novel drug therapies) / Invited Lecture
6TH Annual Partners Physicians Day
2005
Ophthalmology For The Internist: Retinal infections (Toxoplasmic; AIDS- Related
Retinopathy; Herpetic Retinitis; Endogenous Endophthalmitis) / Invited Lecture
6TH Annual Partners Physicians Day
2006, 2007
Infectious Retinitis / Invited Lecture
Massachusetts General Hospital–HIV Conference
2009
Diabetic Retinopathy / Resident Lecture
Massachusetts Eye and Ear Infirmary
2009
Case 33-2010 — A 22-Year-Old Woman with Blurred Vision and Renal Failure / Invited
Lecture (Clinical Pathologic Conference)
MGH Medicine Case Conference, July 31, 2009, Massachusetts General Hospital
2010
Infectious Retinitis / Resident Lecture
Massachusetts Eye and Ear Infirmary
2010
Infectious Retinitis / Plenary Talk
MGH–HOPE Conference –several African countries
2010
Scleral Buckling Pearls / Invited Lecture
Vitreoretinal Course, Massachusetts Eye and Ear Infirmary
2011
Diabetic Retinopathy / Resident Lecture
Massachusetts Eye and Ear Infirmary
2011
Vitreoretinal Course / Invited Lecture
Scleral Buckling Pearls
Massachusetts Eye and Ear Infirmary
2012
Retina Diseases Seen in ED / Resident Lecture
Massachusetts Eye and Ear Infirmary
2012
Historical Background on the Development of Photodynamic Therapy / Plenary Talk
Founders Luncheon, May 2012, Massachusetts Eye and Ear Infirmary
2013
Diabetic Retinopathy / Invited Lecture
MGH Endocrine Conference, January 22, 2013, Massachusetts General Hospital
2013
Infectious Retinitis: The Importance of a Good History / Plenary Talk (Class Speaker)
Alumni Meeting, June 2013, Massachusetts Eye and Ear Infirmary
2013
Scleral Buckling Pearls / Invited Lecture
Vitreoretinal Course, July 2013, Massachusetts Eye and Ear Infirmary
2014
Fluorescein Angiography Lab / Resident Lecture
February 7, Massachusetts Eye and Ear Infirmary
2014
Diabetic Retinopathy / Invited Lecture
MGH Endocrine Conference, February 11, 2014, Massachusetts General Hospital
2014
Scleral Buckling Pearls / Invited Lecture
Vitreoretinal Course, July 2014, Massachusetts Eye and Ear Infirmary
2014
Infectious Retinitis / Resident Lecture
June 13, Massachusetts Eye and Ear Infirmary
2014
Diabetic Retinopathy / Resident Lecture
October 30 Massachusetts Eye and Ear Infirmary
REPORT OF REGIONAL, NATIONAL, AND INTERNATIONAL INVITED TEACHING AND
PRESENTATIONS
Invited Presentations and Courses
Regional
1993
Management of Diabetic Retinopathy / Plenary Talk
Massachusetts Society of Optometrists, Lawrence, MA
1994
Update on Retinal Diseases for the Anterior Segments: Cataract Surgery and Diabetic
Retinopathy / Invited Lecture
Yale University School of Medicine, New Haven, CT
1994
Update on Retinal Diseases for the Anterior Segment: Peripheral Retinal Abnormalities and
Prophylaxis of Retinal Detachment / Invited Lecture
Yale University School of Medicine, New Haven, CT
1996
What’s New–Updates and Perspectives / Plenary Talk
The New England Ophthalmological Society, Boston, MA
1996
Results of the Endophthalmitis Vitrectomy Study / Plenary Talk
The New England Ophthalmological Society
1996
Infectious Retinitis / Invited Lecture
Boston University / Tufts Lecture Series
1997
Management of Diabetic Retinopathy / Invited Lecture
Rhode Island Hospital / Brown Medical School, Providence, RI
1997
Infectious Retinitis / Invited Lecture
Boston University / Tufts Lecture Series
1999
Outpatient Management of Postoperative Endophthalmitis / Plenary Talk
Interactive Retina Specialists Meeting, New England Ophthalmological Society, Boston,
MA
2001
Advances in Retinal Diseases: AIDS-related Retinopathies, Management of Post-op
Endophthalmitis, Diabetic Retinopathy, and Case Presentations / Invited Lectures
Kevin Hill Ophthalmology Course, Colby College, Waterville, ME
2002
Diagnosis of Ocular Lymphoma Using PCR Amplification for IgH Gene Rearrangement /
Plenary Talk
Nantucket Retina 2002, Nantucket, MA
2003
The Risks And Benefits Of Intravitreal Steroids / Plenary Talk and Panel Discussion
Retina Subspecialty Session, New England Ophthalmological Society, Boston, MA
2008
Infectious Retinitis / Grand Rounds
Boston University Medical Center
2012
Retinal Vasculopathies in Young Patients / Honorary Lecture
Robert Haimovici Lecture, Boston University, April 7, 2012
2012
Infectious Retinitis: The Importance of a Good History / Honorary Lecture
Robert Haimovici Lecture, Boston University, April 7, 2012
2013
An Update on Toxoplasmic Retinitis / Plenary Talk
12th Annual Downeast Ophthalmology Symposium, Bar Harbor, ME, Sept 20-22, 2013
2013
Management of Infectious Retinitis: The Importance of a Good History / Plenary Talk
12th Annual Downeast Ophthalmology Symposium, Bar Harbor, ME, Sept 20-22, 2013
2013
Challenging Inflammatory/Infectious Cases / Plenary Talk
12th Annual Downeast Ophthalmology Symposium, Bar Harbor, ME, Sept 20-22, 2013
2013
Infectious Disease in Ophthalmology / Moderator
New England Ophthalmological Society, December 13, 2013,
National
1995
Photodynamic Therapy for Choroidal Melanoma / Plenary Talk
International Congress of Ocular Oncology, Philadelphia, PA
1996
Photodynamic Therapy of Pigmented Choroidal Melanomas / Plenary Talk
Ophthalmic Laser Surgical Society, Inc., New York, NY
1996
Advanced HIV and AIDS Training, Ocular Complications of HIV Disease / Plenary Talk
Pennsylvania AIDS Education and Training Center, Harrisburg, PA
1998
Development of a Photodynamic Therapy for the Treatment of Ocular Melanoma / Plenary
Talk
Cleveland Clinic–Cole Eye Institute
2008
Academy Café: Retina / Invited Panelist
American Academy of Ophthalmology Annual Meeting, Atlanta, GA
2009
Infectious Retinitis / Invited Lecture
University of Illinois at Chicago
2009
Infectious Retinitis / Grand Rounds
Cornell University, Ithaca, NY
2009
When Ophthalmologists Call ID / Plenary Talk
Infectious Diseases Society of America, Philadelphia, PA
2011
A Bug’s Life–latest on infectious retinitis / Plenary Talk
American Academy of Ophthalmology Subspecialty Day, Orlando, FL
2013
Fluorescein/Interesting Cases Conference / Moderator and Contributor
Retina Society 46th Annual Meeting, Beverly Hills, CA, September 26-29, 2013
2014
Posterior Uveitis / Plenary Talk
Symposium: Clinical Pearls in the Diagnosis of Masquerades in Infectious and
Inflammatory Disease of the Eye, American Academy of Ophthalmology Annual Meeting,
October 20
International
1994
Establishment of Pigmented Choroidal Melanomas in an Animal Model / Plenary Talk
(Abstract)
Club Jules Gonin, Versailles, France
1995
Photodynamic Therapy of Experimental Pigmented Choroidal Melanomas Using BPD-MA
and CASPc / Plenary Talk
International Symposium on Experimental and Clinical Ocular Pharmacology and
Pharmaceutics, Geneva, Switzerland
1996
Photodynamic Therapy of Pigmented Choroidal Melanomas / Plenary Talk (Abstract)
Club Jules Gonin, Berg, Switzerland
1998
Photodynamic Therapy of Pigmented Choroidal Melanomas / Plenary Talk
Journees Romandes D’Ophthalmologie, Geneva, Switzerland
2000
Experimental Oncology – Intraocular Tumors / Invited Lecture
First International Course on Photodynamic Therapy, Lausanne, Switzerland
2000
Photodynamic Therapy of Experimental Choroidal Melanoma Using Multiphoton
Excitation / Plenary Talk (Abstract)
Club Jules Gonin, Taormina, Sicily
2009
Infectious Retinitis, Diabetic Retinopathy, Interesting Cases / Plenary Talk
Cape Eye Institute, Cape Town, South Africa
2009
Age related macular degeneration: current therapies and future directions / Plenary Talk
Combretum Retina Meeting, South Africa
2009
Infectious Retinitis: the importance of a good history / Plenary Talk
Combretum Retina Meeting, South Africa
2009
Challenging inflammatory/infectious cases / Plenary Talk
Combretum Retina Meeting, South Africa
2009
Non-AMD maculopathies / Plenary Talk
Combretum Retina Meeting, South Africa
2009
Dots, spots, flecks and what else? / Plenary Talk
Combretum Retina Meeting, South Africa
2009
Retinal vasculopathies in young patients / Plenary Talk
Combretum Retina Meeting, South Africa
2009
Macular leakage / Plenary Talk
Combretum Retina Meeting, South Africa
2009
VEGF Blocking Therapy: historical background, current application and future directions /
Plenary Talk
Combretum Retina Meeting, South Africa
2009
Clinical cases: infectious? / Plenary Talk
Combretum Retina Meeting, South Africa
2009
Posterior uveitis / Plenary Talk
Combretum Retina Meeting, South Africa
2010
Fungal Endophthalmitis / Plenary Talk
Infectious Diseases Society of America, Vancouver, Canada
2011
Infectious Retinitis, Challenging Inflammatory and Infectious Cases / Plenary Talk
Department of Ophthalmology, Chang Gung Memorial Hospital, Lin Kou, Taiwan
2012
Infectious Retinitis / Plenary Talk
World Ophthalmology Congress, Abu Dhabi, United Arab Emirates
2013
Infectious Retinitis: The Importance of a Good History / Plenary Talk
Cape Eye Institute, Cape Town, South Africa, August 2013
2013
Posterior Segment Complications After Cataract Surgery / Plenary Talk
Cape Eye Institute, Cape Town, South Africa, August 2013
2013
Infectious Retinitis: The Importance of a Good History / Plenary Talk
South African Society of Cataract and Refractive Surgery, Zambia, August 2013
2013
Posterior Segment Complications After Cataract Surgery / Plenary Talk
South African Society of Cataract and Refractive Surgery, Zambia, August 2013
REPORT OF CLINICAL ACTIVITIES AND INNOVATIONS
Current Licensure and Certification
1985–
Massachusetts Medical License Registration
1991
American Board of Ophthalmology Certification
Practice Activities
1989–1990
Ambulatory care
(consultation, surgeries, and
other procedures), acute
care, and urgent care
Retina Service,
Massachusetts Eye and Ear
Infirmary
1 session per week
1990–2006
Ambulatory care
(consultation, surgeries, and
other procedures), acute
care, and urgent care
Retina Service,
Massachusetts Eye and Ear
Infirmary
2 sessions per week
1996
Ambulatory care
(consultation)
Spaulding Rehabilitation
Hospital
Ad hoc
2006–
Ambulatory care
(consultation, surgeries, and
other procedures), acute
care, and urgent care
Retina Service,
Massachusetts Eye and Ear
Infirmary
3 sessions per week
2009–
Ambulatory care
(consultation)
Massachusetts General
Hospital
Ad hoc
2009–
Ambulatory care
(consultation)
Brigham and Women’s
Hospital
Ad hoc
Clinical Innovations
Development of an
animal model of
choroidal melanoma
We developed a pigmented model of choroidal melanoma in New Zealand
albino rabbits. Because most human uveal melanomas are pigmented, this
model was more suitable than existing non-pigmented models for the
preclinical evaluation of newly developed phototherapies for uveal melanoma.
Selected citations:
Hu LK, Huh K, Gragoudas ES, Young LH. Establishment of pigmented
choroidal melanomas in a rabbit model. Retina. 1994;14(3):264-9. PubMed
PMID: 7973123.
Pineda R 2nd, Theodossiadis PG, Gonzalez VH, Hu LK, Hart LJ, Gragoudas
ES, Young LH. Establishment of a rabbit model of extrascleral extension of
ocular melanoma. Retina. 1998;18(4):368-72. PubMed PMID: 9730182.
Development of
photodynamic therapy
for uveal melanoma
Utilizing our rabbit model of pigmented model of choroidal melanoma, we
performed investigations of photodynamic therapy (PDT) with
photosensitizing agents (including a liposomal preparation of benzoporphyrin
derivative (BPD), verteporfin). These studies formed the preclinical basis of
verteporfin PDT, one of the current treatment options for the management of
uveal melanoma.
Selected citations:
Gonzalez VH, Hu LK, Theodossiadis PG, Flotte TJ, Gragoudas ES, Young
LH. Photodynamic therapy of pigmented choroidal melanomas. Invest
Ophthalmol Vis Sci. 1995 Apr;36(5):871-8. PubMed PMID: 7706035.
Young LH, Howard MA, Hu LK, Kim RY, Gragoudas ES. Photodynamic
therapy of pigmented choroidal melanomas using a liposomal preparation of
benzoporphyrin derivative. Arch Ophthalmol. 1996 Feb;114(2):186-92.
PubMed PMID: 8573023.
Kim RY, Hu LK, Foster BS, Gragoudas ES, Young LH. Photodynamic
therapy of pigmented choroidal melanomas of greater than 3-mm thickness.
Ophthalmology. 1996 Dec;103(12):2029-36. PubMed PMID: 9003336.
Angiographic method
using green porphyrins
in primate eyes
We developed an angiographic method to observe the condition of blood
vessels, including neovasculature in the eyes of living primates using green
porphyrins and light at a wavelength of 550-700 nm to effect fluorescence.
This method formed the basis of preclinical models of vascular-targeting
therapies for neovascular ocular disease. Verteporfin photodynamic therapy
(PDT) was subsequently approved by health authorities worldwide as the first
pharmacologic treatment for neovascular age-related macular degeneration
(AMD).
Citation:
Miller JW, Young LHY, Gragoudas ES, inventors; Massachusetts Eye and
Ear Infirmary, assignee. US Patent No. 5,707,986. January 13, 1998.
REPORT OF TECHNOLOGICAL AND OTHER SCIENTIFIC INNOVATIONS
Genomic and
proteomic
approaches in the
diagnosis and
treatment of
toxoplasmic retinitis
Clinical evidence suggests that multiple factors determine patient response to
conventional antibiotic treatment for toxoplasmic retinitis, including pathogen
virulence, host response/susceptibility, and strain-specific response to antibiotic
treatment. In a current collaboration with a former research fellow in Brazil and
colleagues at MIT, we are developing a novel non-invasive assay to correlate
Toxoplamsa gondii strain with disease outcome using oligonucleotide
microarrays and peptide screening. Additionally, we are conducting genomic
studies to correlate single-nucleotide polymorphisms (SNPs) with host
susceptibility and determining antibiotic susceptibility and host-pathogen
interactions of various Toxoplasma strains. These studies will facilitate the
treatment of toxoplasmic retinitis.
Select citations:
Bessa TF, Cordeiro CA, Gonçalves RM, Young LH, Campos WR, Oréfice F,
Teixeira AL. Increased serum levels of soluble tumor necrosis factor receptor-2
(sTNFR2) in patients with active toxoplasmic retinochoroiditis. Braz J Infect
Dis. 2012 Nov-Dec;16(6):540-4. doi: 10.1016/j.bjid.2012.07.009. Epub 2012
Nov 8. PubMed PMID: 23141990.
Cordeiro CA, Moreira PR, Bessa TF, Costa GC, Dutra WO, Campos WR,
Oréfice F, Young LH, Teixeira AL. Interleukin-6 gene polymorphism (-174
G/C) is associated with toxoplasmic retinochoroiditis. Acta Ophthalmol. 2013
Jun;91(4):e311-4. doi: 10.1111/aos.12046. Epub 2013 Jan 22. PubMed PMID:
23336844..
Melo MB, Nguyen QP, Cordeiro C, Hasan MA, Yang N, Mckell R, Rosowki
EE, Julien L, Butty V, Darde ML, Ajzenberg D, Fitzgerald K, Young, LH,
Saeij, JPJ. Transcriptional analysis of murine macrophages infected with
different Toxoplasma strains identifies novel regulation of host signaling
pathways. PLoS Pathogens 2013;9(12):e1003779. doi:
10.1371/journal.ppat.1003779. Epub 2013 Dec 19. PubMed PMID: 24367253;
PubMed Central PMCID: PMC3868521.
REPORT OF EDUCATION OF PATIENTS AND SERVICE TO THE COMMUNITY
Activities
1997
Treatment For Ocular Melanoma / Plenary Talk
Massachusetts Lions Club, Hyannis, MA
1998
Treatment For Ocular Melanoma / Plenary Talk
Massachusetts Lions Club, Provincetown, MA
1999
An Alternative Treatment For Ocular Tumors / Plenary Talk
Massachusetts Lions Club, Hyannis, MA
2004
Photodynamic Therapy For Ocular Melanoma / Plenary Talk
Massachusetts Lions Club (hosted by Massachusetts Eye and Ear Infirmary), Boston, MA
2011
Common Age-Related Retinal Diseases / Plenary Talk (Keynote Speaker)
The Senior Connection
Massachusetts Commission for the Blind and Visually Impaired, Randolph, MA
2012
The Diabetes Epidemic / Plenary Talk (Keynote)
Aruba Lions 65th Annual Meeting, Aruba
Recognition
2006
2000 Notable American Women
American Biographical Institute
2007
America’s Top
Ophthalmologists
Consumers’ Research Council of America
2007–
Best Doctors in America
Best Doctors, Inc.
2007
Top Doctors (Ophthalmology)
Boston Magazine
2008–
Castle Connolly Top Docs
(Regional)
Castle Connolly Medical Ltd.
2010–
Boston Super Doctors
MSP Communications
2011–
Top Doctors
US News & World Report
REPORT OF SCHOLARSHIP
PUBLICATIONS
Peer reviewed publications in print or other media
Research investigations
1. Young LH, Dowling JE. Monoclonal antibodies distinguish subtypes of retinal horizontal cells.
Proc Natl Acad Sci U S A. 1984 Oct;81(19):6255-9. PubMed PMID: 6385010; PubMed Central
PMCID: PMC391899.
2. Young LH, Klavinskis LS, Oldstone MB, Young JD. In vivo expression of perforin by CD8+
lymphocytes during an acute viral infection. J Exp Med. 1989 Jun 1;169(6):2159-71. Erratum in: J
Exp Med 1989 Dec 1;170(6):2191. PubMed PMID: 2471775; PubMed Central PMCID:
PMC2189355.
3. Young LH, Dowling JE. Localization of cyclic adenosine monophosphate in the teleost retina:
effects of dopamine and prolonged darkness. Brain Res. 1989 Dec 11;504(1):57-63. PubMed
PMID: 2557125.
4. Young LH, Peterson LB, Wicker LS, Persechini PM, Young JD. In vivo expression of perforin by
CD8+ lymphocytes in autoimmune disease. Studies on spontaneous and adoptively transferred
diabetes in nonobese diabetic mice. J Immunol. 1989 Dec 15;143(12):3994-9. PubMed PMID:
2480383.
5. Young LH, Dowling JE. A monoclonal antibody specific to Müller cells and selective synaptic
sites in the retina. Invest Ophthalmol Vis Sci. 1990 Apr;31(4):607-16. PubMed PMID: 1692309.
6. Tabatabay CA, Young LH, D'Amico DJ, Kenyon KR. Immunocytochemical localization of
gentamicin in the rabbit retina following intravitreal injection. Arch Ophthalmol. 1990
May;108(5):723-6. PubMed PMID: 2185724.
7. Young LH, Foster CS, Young JD. In vivo expression of perforin by natural killer cells during a
viral infection. Studies on uveitis produced by herpes simplex virus type I. Am J Pathol. 1990
May;136(5):1021-30. PubMed PMID: 2190470; PubMed Central PMCID: PMC1877436.
8. Parr EL, Young LH, Parr MB, Young JD. Granulated metrial gland cells of pregnant mouse
uterus are natural killer-like cells that contain perforin and serine esterases. J Immunol. 1990 Oct
1;145(7):2365-72. PubMed PMID: 1975830.
9. Young LH, Joag SV, Zheng LM, Lee CP, Lee YS, Young JD. Perforin-mediated myocardial
damage in acute myocarditis. Lancet. 1990 Oct 27;336(8722):1019-21. PubMed PMID: 1699101.
10. Young LH, Joag SV, Lin PY, Luo SF, Zheng LM, Liu CC, Young JD. Expression of cytolytic
mediators by synovial fluid lymphocytes in rheumatoid arthritis. Am J Pathol. 1992
May;140(5):1261-8. PubMed PMID: 1580335; PubMed Central PMCID: PMC1886510.
11. Hu LK, Huh K, Gragoudas ES, Young LH. Establishment of pigmented choroidal melanomas in a
rabbit model. Retina. 1994;14(3):264-9. PubMed PMID: 7973123.
12. Gonzalez VH, Hu LK, Theodossiadis PG, Flotte TJ, Gragoudas ES, Young LH. Photodynamic
therapy of pigmented choroidal melanomas. Invest Ophthalmol Vis Sci. 1995 Apr;36(5):871-8.
PubMed PMID: 7706035.
13. Hu LK, Hasan T, Gragoudas ES, Young LH. Photoimmunotherapy of human uveal melanoma
cells. Exp Eye Res. 1995 Oct;61(4):385-91. PubMed PMID: 8549679.
14. Young LH, Howard MA, Hu LK, Kim RY, Gragoudas ES. Photodynamic therapy of pigmented
choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch
Ophthalmol. 1996 Feb;114(2):186-92. PubMed PMID: 8573023.
15. Kim RY, Hu LK, Foster BS, Gragoudas ES, Young LH. Photodynamic therapy of pigmented
choroidal melanomas of greater than 3-mm thickness. Ophthalmology. 1996 Dec;103(12):202936. PubMed PMID: 9003336.
16. Kim RY, Hu LK, Flotte TJ, Gragoudas ES, Young LH. Digital angiography of experimental
choroidal melanomas using benzoporphyrin derivative. Am J Ophthalmol. 1997 Jun;123(6):810-6.
PubMed PMID: 9535625.
17. Haynie GD, Shen TT, Gragoudas ES, Young LH. Flow cytometry analysis of peripheral blood
lymphocytes in patients with choroidal melanoma. Am J Ophthalmol. 1997 Sep;124(3):357-61.
PubMed PMID: 9439361.
18. Park SS, Girard B, Font RL, Hauw JJ, Young LH. Immunohistochemical localization of
ganciclovir in the human retina. Curr Eye Res. 1998 Jun;17(6):663-7. PubMed PMID: 9663857.
19. Pineda R 2nd, Theodossiadis PG, Gonzalez VH, Hu LK, Hart LJ, Gragoudas ES, Young LH.
Establishment of a rabbit model of extrascleral extension of ocular melanoma. Retina.
1998;18(4):368-72. PubMed PMID: 9730182.
20. Krause M, Kwong KK, Xiong J, Gragoudas ES, Young LH. MRI of blood volume and cellular
uptake of superparamagnetic iron in an animal model of choroidal melanoma. Ophthalmic Res.
2002 Jul-Aug;34(4):241-50. PubMed PMID: 12297697.
21. Hu L, Wu X, Song Y, Young LH, Gragoudas ES. [Photodynamic therapy of pigmented choroidal
melanomas in rabbits]. Zhonghua Yan Ke Za Zhi. 2002 Aug;38(8):491-4. Chinese. PubMed
PMID: 12410990.
22. Krause MH, Xiong J, Gragoudas ES, Young LH. Treatment of experimental choroidal melanoma
with an Nd:yttrium-lanthanum-fluoride laser at 1047 nm. Arch Ophthalmol. 2003
Mar;121(3):357-63. PubMed PMID: 12617706.
23. Krause MH, Kwong KK, Xiong J, Gragoudas ES, Young LH. MRI of blood volume with MS 325
in experimental choroidal melanoma. Magn Reson Imaging. 2003 Sep;21(7):725-32. PubMed
PMID: 14559336.
24. Krause MH, Kwong KK, Gragoudas ES, Young LH. MRI of blood volume with
superparamagnetic iron in choroidal melanoma treated with thermotherapy. Magn Reson Imaging.
2004 Jul;22(6):779-87. PubMed PMID: 15234446.
25. Yu SY, Damico FM, Viola F, D'Amico DJ, Young LH. Retinal toxicity of intravitreal
triamcinolone acetonide: a morphological study. Retina. 2006 May-Jun;26(5):531-6. PubMed
PMID: 16770259.
26. Yi K, Mujat M, Park BH, Sun W, Miller JW, Seddon JM, Young LH, de Boer JF, Chen TC.
Spectral domain optical coherence tomography for quantitative evaluation of drusen and
associated structural changes in non-neovascular age-related macular degeneration. Br J
Ophthalmol. 2009 Feb;93(2):176-81. doi: 10.1136/bjo.2008.137356. Epub 2008 Aug 12. PubMed
PMID: 18697811; PubMed Central PMCID: PMC2628537.
27. Trichonas G, Manola A, Morizane Y, Thanos A, Koufomichali X, Papakostas TD, Montezuma S,
Young L, Miller JW, Gragoudas E, Vavvas D. A novel nonradioactive method to evaluate
vascular barrier breakdown and leakage. Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1677-82.
doi: 10.1167/iovs.09-4193. Epub 2009 Oct 29. PubMed PMID: 19875655.
28. Tibbetts MD, Shah CP, Young LH, Duker JS, Maguire JI, Morley MG. Treatment of acute retinal
necrosis. Ophthalmology. 2010 Apr;117(4):818-24. doi: 10.1016/j.ophtha.2009.09.001. Epub
2010 Jan 15. PubMed PMID: 20079537.
29. Thanos A, Morizane Y, Murakami Y, Giani A, Mantopoulos D, Kayama M, Roh MI, Michaud N,
Pawlyk B, Sandberg M, Young LH, Miller JW, Vavvas DG. Evidence for baseline retinal
pigment epithelium pathology in the Trp1-Cre mouse. Am J Pathol. 2012 May;180(5):1917-27.
doi: 10.1016/j.ajpath.2012.01.017. Epub 2012 Mar 17. PubMed PMID: 22429967; PubMed
Central PMCID: PMC3349832.
30. Bessa TF, Cordeiro CA, Gonçalves RM, Young LH, Campos WR, Oréfice F, Teixeira AL.
Increased serum levels of soluble tumor necrosis factor receptor-2 (sTNFR2) in patients with
active toxoplasmic retinochoroiditis. Braz J Infect Dis. 2012 Nov-Dec;16(6):540-4. doi:
10.1016/j.bjid.2012.07.009. Epub 2012 Nov 8. PubMed PMID: 23141990.
31. Cordeiro CA, Moreira PR, Bessa TF, Costa GC, Dutra WO, Campos WR, Oréfice F, Young LH,
Teixeira AL. Interleukin-6 gene polymorphism (-174 G/C) is associated with toxoplasmic
retinochoroiditis. Acta Ophthalmol. 2013 Jun;91(4):e311-4. doi: 10.1111/aos.12046. Epub 2013
Jan 22. PubMed PMID: 23336844.
32. Melo MB, Nguyen QP, Cordeiro C, Hasan MA, Yang N, Mckell R, Rosowki EE, Julien L, Butty
V, Darde ML, Ajzenberg D, Fitzgerald K, Young, LH, Saeij, JPJ. Transcriptional analysis of
murine macrophages infected with different Toxoplasma strains identifies novel regulation of host
signaling pathways. PLoS Pathogens 2013;9(12):e1003779. doi: 10.1371/journal.ppat.1003779.
Epub 2013 Dec 19. PubMed PMID: 24367253; PubMed Central PMCID: PMC3868521.
33. Kirk D, Camejo A, Melo MB, Cordeiro C, Julien L, Grotenbreg GM, Frickel E, Ploegh HL,
Young LH, Saeij J. Toxoplasma gondii Superinfection and Virulence during Secondary Infection
Correlate with the Exact ROP5/ROP18 Allelic Combination. MBio. 2015 Feb 24;6(2). pii:
e02280-14. doi: 10.1128/mBio.02280-14.
Other peer-reviewed publications
Case reports or series
1. Young LH, Appen RE. Ischemic oculopathy. A manifestation of carotid artery disease. Arch
Neurol. 1981 Jun;38(6):358-6. PubMed PMID: 7236064.
2. Young LH, Gragoudas ES. Macular uveal melanoma treated with proton beam irradiation. 10year follow-up observation with histopathologic correlation. Retina. 1994;14(1):43-6. PubMed
PMID: 8016461.
3. Young LH, Egan KM, Walsh SM, Gragoudas ES. Familial uveal melanoma. Am J Ophthalmol.
1994 Apr 15;117(4):516-20. PubMed PMID: 8154536.
4. Ray S, Topping T, Young LH. Spontaneous peeling of epiretinal membrane associated with
Nd:YAG laser injury. Arch Ophthalmol. 2001 Jan;119(1):137-9. PubMed PMID: 11146742.
5. Chen TC, Young LH. Sturge-Weber syndrome (choroidal hemangioma and glaucoma).* J Pediatr
Ophthalmol Strabismus. 2005 Sep-Oct;42(5):320. PubMed PMID: 16250225. (*Cover photo)
6. Young LH, Gross JG, Lai JC, Shakin JL, Thompson JT. Diagnostic and therapeutic challenges.
Retina. 2005 Oct-Nov;25(7):930-5. PubMed PMID: 16205574.
7. Ament CS, Zacks DN, Lane AM, Krzystolik M, D'Amico DJ, Mukai S, Young LH, Loewenstein
J, Arroyo J, Miller JW. Predictors of visual outcome and choroidal neovascular membrane
formation after traumatic choroidal rupture. Arch Ophthalmol. 2006 Jul;124(7):957-66. PubMed
PMID: 16832018.
8. Young LH, Bazari H, Durand ML, Branda JA. Case records of the Massachusetts General
Hospital. Case 33-2010. A 22-year-old woman with blurred vision and renal failure. N Engl J
Med. 2010 Oct 28;363(18):1749-58. doi: 10.1056/NEJMcpc1005308. PubMed PMID: 20979476.
9. Thanos A, Vavvas D, Young LH, Foster CS. Choroidal neovascular membrane formation and
retinochoroidopathy in a patient with systemic langerhans cell histiocytosis: a case report and
review of the literature. Case Rep Ophthalmol. 2012 Jan;3(1):128-35. Epub 2012 Apr 13. PubMed
PMID: 23002392; PubMed Central PMCID: PMC3448115.
10. Yiu G, Young LH. Progressive outer retinal necrosis presenting as cherry red spot. Ocul Immunol
Inflamm. 2012 Oct;20(5):384-6. doi: 10.3109/09273948.2012.710705. Epub 2012 Sep 7. PubMed
PMID: 22957726.
11. Yiu G, Young LH. Choroidal osteomas.* JAMA Ophthalmol. 2013 Jan;131(1):124. doi:
10.1001/jamaophthalmol.2013.568. PubMed PMID: 23307230. (*Cover photo)
12. Taniguchi EV, Young LH, Shen LQ. Optic nerve pit and associated macular detachment. JAMA
Ophthalmol. 2015 Jan 8;133(1):e141775. doi: 10.1001/jamaophthalmol.2014.1775. Epub 2015 Jan
8. PubMed PMID: 25569314.
Reviews
1. Young LH, Liu CC, Joag S, Rafii S, Young JD. How lymphocytes kill. Annu Rev Med.
1990;41:45-54. Review. PubMed PMID: 2184743.
2. De La Paz MA, Young LHY. Acute retinal necrosis syndrome. Semin Ophthalmol. 1993
Jan;8(1):61-69.
3. Liu CC, Young LH, Young JD. Lymphocyte-mediated cytolysis and disease. N Engl J Med. 1996
Nov 28;335(22):1651-9. Review. PubMed PMID: 8929363.
4. Foster BS, Gragoudas ES, Young LH. Photodynamic therapy of choroidal melanoma. Int
Ophthalmol Clin. 1997 Fall;37(4):117-26. Review. PubMed PMID: 9480300.
5. You TT, Young LH. Retinal manifestations of gastrointestinal conditions. Int Ophthalmol Clin.
1998 Winter;38(1):197-220. Review. PubMed PMID: 9532482.
6. Kim RY, Young LHY. Use of Photodynamic Therapy for Treatment of Ocular Malignancies.
Ophthalmol Clin North Am. 1999 Jan;12(2):167-176.
7. Youssri AI, Young LH. Closed-globe contusion injuries of the posterior segment. Int Ophthalmol
Clin. 2002 Summer;42(3):79-86. Review. PubMed PMID: 12131585.
8. Lit ES, Young LH. Anterior and posterior segment intraocular foreign bodies. Int Ophthalmol
Clin. 2002 Summer;42(3):107-20. Review. PubMed PMID: 12131588.
9. Zacks DN, Hart L, Young LH. Ultrasonography in the traumatized eye: intraocular foreign body
versus artifact. Int Ophthalmol Clin. 2002 Summer;42(3):121-8. PubMed PMID: 12131589.
10. Acharya N, Young L. Sustained-release drug implants for the treatment of intraocular disease. Int
Ophthalmol Clin. 2004 Summer;44(3):33-9. Review. PubMed PMID: 15211175.
11. Kiss S, Damico FM, Young LH. Ocular manifestations and treatment of syphilis. Semin
Ophthalmol. 2005 Jul-Sep;20(3):161-7. Review. PubMed PMID: 16282150.
12. Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. Semin Ophthalmol. 2005 JulSep;20(3):183-90. Review. PubMed PMID: 16282153.
13. Damico FM, Kiss S, Young LH. Sympathetic ophthalmia. Semin Ophthalmol. 2005 JulSep;20(3):191-7. Review. PubMed PMID: 16282154.
14. Paul Chan RV, Young LH. Treatment options for metastatic tumors to the choroid. Semin
Ophthalmol. 2005 Oct-Dec;20(4):207-16. Review. PubMed PMID: 16361217.
15. Kim RY, Gragroudas ES, Young LH. Future laser approaches in melanoma treatment. Int
Ophthalmol Clin. 2006 Winter;46(1):27-39. Review. PubMed PMID: 16365553.
16. Ament CS, Young LH. Ocular manifestations of helminthic infections: onchocersiasis,
cysticercosis, toxocariasis, and diffuse unilateral subacute neuroretinitis. Int Ophthalmol Clin.
2006 Spring;46(2):1-10. Review. PubMed PMID: 16770150.
17. Wiegand TW, Young LH. Cytomegalovirus retinitis. Int Ophthalmol Clin. 2006 Spring;46(2):91110. Review. PubMed PMID: 16770157.
18. Koo L, Young LH. Management of ocular toxoplasmosis. Int Ophthalmol Clin. 2006
Spring;46(2):183-93. Review. PubMed PMID: 16770162.
19. Singh RP, Young LH. Diagnostic tests for posterior segment inflammation. Int Ophthalmol Clin.
2006 Spring;46(2):195-208. Review. PubMed PMID: 16770163.
20. Chang S, Young LH. Acute retinal necrosis: an overview. Int Ophthalmol Clin. 2007
Spring;47(2):145-54. Review. PubMed PMID: 17450014.
21. Waheed NK, Young LH. Intraocular foreign body related endophthalmitis. Int Ophthalmol Clin.
2007 Spring;47(2):165-71. Review. PubMed PMID: 17450016.
22. Pachydaki SI, Young LH. Genetics of hereditary vitreoretinal degenerations. Semin Ophthalmol.
2007 Oct-Dec;22(4):219-27. Review. PubMed PMID: 18097985.
23. Rashid S, Young LH. Progression of diabetic retinopathy and maculopathy after
phacoemulsification surgery. Int Ophthalmol Clin. 2010 Winter;50(1):155-66. doi:
10.1097/IIO.0b013e3181c555cf. Review. PubMed PMID: 20057304.
24. Cordeiro CA, Moreira PR, Dutra WO, Young L, Campos WR, Oréfice F, Teixeira Júnior AL.
[Immunology of the toxoplasmic retinochoroiditis]. Arq Bras Oftalmol. 2010 Nov-Dec;73(6):54851. Review. Portuguese. PubMed PMID: 21271035.
25. Chang GC, Young LH. Sympathetic ophthalmia. Semin Ophthalmol. 2011 Jul-Sep;26(4-5):31620. doi: 10.3109/08820538.2011.588658. Review. PubMed PMID: 21958181.
26. Englander M, Young LH. Ocular toxoplasmosis: advances in detection and treatment. Int
Ophthalmol Clin. 2011 Fall;51(4):13-23. doi: 10.1097/IIO.0b013e31822d663b. Review. PubMed
PMID: 21897136.
27. Daniels AB, Kohanim S, Huynh N, Durand ML, Young LH. Antiviral chemoprophylaxis for
ocular viral infections in hematopoietic stem cell and bone marrow transplant patients. Int
Ophthalmol Clin. 2011 Fall;51(4):53-66. doi: 10.1097/IIO.0b013e31822d65e9. Review. PubMed
PMID: 21897140.
28. Yiu G, Young L, Gilmore M, Chodosh J. Prophylaxis against postoperative endophthalmitis in
cataract surgery. Int Ophthalmol Clin. 2011 Fall;51(4):67-83. doi:
10.1097/IIO.0b013e31822d6b3d. Review. PubMed PMID: 21897141.
29. Huynh N, Daniels AB, Kohanim S, Young LH. Medical treatment for cytomegalovirus retinitis.
Int Ophthalmol Clin. 2011 Fall;51(4):93-103. doi: 10.1097/IIO.0b013e31822d6834. Review.
PubMed PMID: 21897143.
30. Sandhu HS, Young LH. Ocular Siderosis. Int Ophthalmol Clin. 2013 Fall;53(4):177-184. PubMed
PMID: 24088944.
31. Haddock LJ, Ramsey DJ, Young LH. Complications of subspecialty ophthalmic care:
endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications.
Semin Ophthalmol. 2014 Nov;29(5-6):257-62. doi: 10.3109/08820538.2014.959616. PubMed
PMID: 25325851.
32. Ramsey DJ, Haddock LJ, Young LH, Eliott D. Complications of Subspecialty Ophthalmic Care:
Systemic Complications from the Intravitreal Administration of Agents that Target the Vascular
Endothelial Growth Factor Pathway. Semin Ophthalmol. 2014 Nov;29(5-6):263-75. doi:
10.3109/08820538.2014.959195. PubMed PMID: 25325852.
33. Qian CX, Young LH. The Impact of Cataract Surgery on AMD Development and Progression.
Semin Ophthalmol. 2014 Nov;29(5-6):301-11. doi: 10.3109/08820538.2014.962166. PubMed
PMID: 25325855.
Research publications without named authorship (*Member of the investigative team cited in the
appendix of the manuscript)
1. PKC-DRS2 Group,* Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati
L, Zhi XE. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
Ophthalmology. 2006 Dec;113(12):2221-30. Epub 2006 Sep 20. PubMed PMID: 16989901.
2. Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati
L; PKC-DRS2 Study Group.* Effect of ruboxistaurin on the visual acuity decline associated
with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci. 2009 Jan;50(1):1-4. doi:
10.1167/iovs.08-2473. Epub 2008 Aug 15. PubMed PMID: 18708615.
3. Girach A, Aiello LP, Milton RC, Davis MD, Danis RP, Zhi X, Sheetz MJ, Vignati L; PKC-DRS2
Study Group.* Sustained moderate visual loss as a predictive end point for visual loss in nonproliferative diabetic retinopathy. Eye (Lond). 2009 Jan;23(1):209-14. doi: 10.1038/eye.2008.324.
Epub 2008 Nov 7. PubMed PMID: 18989348.
4. Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup
SM; Dexamethasone DDS Phase II Study Group.* Dexamethasone posterior-segment drug
delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome.
Am J Ophthalmol. 2009 Jun;147(6):1048-54, 1054.e1-2. doi: 10.1016/j.ajo.2008.12.033. Epub
2009 Mar 9. PubMed PMID: 19268890.
5. Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, Guyer
DR, Katz B, Altaweel MM; Pegaptanib in Central Retinal Vein Occlusion Study Group.*
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch
Ophthalmol. 2009 Apr;127(4):374-80. doi: 10.1001/archophthalmol.2009.14. PubMed PMID:
19365011.
6. Gardner TW, Larsen M, Girach A, Zhi X; Protein Kinase C Diabetic Retinopathy Study (PKCDRS2) Study Group.* Diabetic macular oedema and visual loss: relationship to location, severity
and duration. Acta Ophthalmol. 2009 Nov;87(7):709-13. doi: 10.1111/j.1755-3768.2009.01545.x.
Epub 2009 Oct 8. PubMed PMID: 19817721.
7. Kuppermann BD, Chou C, Weinberg DV, Whitcup SM, Haller JA, Blumenkranz MS;
Dexamethasone DDS Phase II Study Group.* Intravitreous dexamethasone effects on different
patterns of diabetic macular edema. Arch Ophthalmol. 2010 May;128(5):642-3. doi:
10.1001/archophthalmol.2010.44. Epub 2010 Mar 8. PubMed PMID: 20212194.
8. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup
SM; Dexamethasone DDS Phase II Study Group.* Randomized controlled trial of an
intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.Arch
Ophthalmol. 2010 Mar;128(3):289-96. doi: 10.1001/archophthalmol.2010.21. PubMed PMID:
20212197.
9. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG;
BRAVO Investigators.* Ranibizumab for macular edema following branch retinal vein
occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010
Jun;117(6):1102-1112.e1. doi: 10.1016/j.ophtha.2010.02.021. Epub 2010 Apr 15. PubMed PMID:
20398941.
10. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG,
Murahashi WY; CRUISE Investigators.* Ranibizumab for macular edema following central
retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology.
2010 Jun;117(6):1124-1133.e1. doi: 10.1016/j.ophtha.2010.02.022. Epub 2010 Apr 9. PubMed
PMID: 20381871.
11. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon
YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group.*
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular
edema due to retinal vein occlusion. Ophthalmology. 2010 Jun;117(6):1134-1146.e3. doi:
10.1016/j.ophtha.2010.03.032. Epub 2010 Apr 24. PubMed PMID: 20417567.
12. Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP; Mbdv Study Group.* Effect
of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and
reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic
Retinopathy Study 2 (PKC-DRS2). Retina. 2011 Jun;31(6):1053-9. doi:
10.1097/IAE.0b013e3181fe545f. PubMed PMID: 21386766.
13. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG,
Murahashi WY.* Sustained benefits from ranibizumab for macular edema following branch retinal
vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011 Aug;118(8):1594602. doi: 10.1016/j.ophtha.2011.02.022. PubMed PMID: 21684606.
14. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG.*
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion:
twelve-month outcomes of a phase III study. Ophthalmology. 2011 Oct;118(10):2041-9. doi:
10.1016/j.ophtha.2011.02.038. Epub 2011 Jun 29. PubMed PMID: 21715011.
15. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon
YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group,* Li J. Dexamethasone
intravitreal implant in patients with macular edema related to branch or central retinal vein
occlusion twelve-month study results. Ophthalmology. 2011 Dec;118(12):2453-60. doi:
10.1016/j.ophtha.2011.05.014. Epub 2011 Jul 20. PubMed PMID: 21764136.
16. Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC;
PKC-DRS and PKC-DRS2 Study Groups.* Oral protein kinase c β inhibition using
ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with
diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the
Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2. Retina. 2011 Nov;31(10):2084-94.
doi: 10.1097/IAE.0b013e3182111669. PubMed PMID: 21862954.
17. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC,
Hopkins JJ, Rubio RG, Ehrlich JS; RISE* and RIDE Research Group. Ranibizumab for diabetic
macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012
Apr;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039. Epub 2012 Feb 11. PubMed PMID:
22330964.
18. Varma R, Bressler NM, Suñer I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG; BRAVO and
CRUISE Study Groups.* Improved vision-related function after ranibizumab for macular edema
after retinal vein occlusion: results from the BRAVO and CRUISE trials.Ophthalmology. 2012
Oct;119(10):2108-18. doi: 10.1016/j.ophtha.2012.05.017. Epub 2012 Jul 18. PubMed PMID:
22817833.
19. AREDS2 Research Group,* Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A,
McBee W, Sperduto R, Ferris FL. The Age-Related Eye Disease Study 2 (AREDS2): study design
and baseline characteristics (AREDS2 report number 1). Ophthalmology. 2012
Nov;119(11):2282-9. doi: 10.1016/j.ophtha.2012.05.027. Epub 2012 Jul 26. PubMed PMID:
22840421; PubMed Central PMCID: PMC3485447.
20. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS.* Long-term effects of ranibizumab on
diabetic retinopathy severity and progression. Arch Ophthalmol. 2012 Sep;130(9):1145-52. doi:
10.1001/archophthalmol.2012.1043. PubMed PMID: 22965590.
21. Danis RP, Domalpally A, Chew EY, Clemons TE, Armstrong J, SanGiovanni JP, Ferris FL 3rd;
AREDS2 Study Group.* Methods and reproducibility of grading optimized digital color fundus
photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). Invest
Ophthalmol Vis Sci. 2013 Jul 8;54(7):4548-54. doi: 10.1167/iovs.13-11804. PubMed PMID:
23620429; PubMed Central PMCID: PMC3706107.
22. Age-Related Eye Disease Study 2 Research Group.* Lutein + zeaxanthin and omega-3 fatty
acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2)
randomized clinical trial. JAMA. 2013 May 15;309(19):2005-15. doi: 10.1001/jama.2013.4997.
Erratum in: JAMA. 2013 Jul 10;310(2):208. PubMed PMID: 23644932.
23. Age-Related Eye Disease Study 2 (AREDS2) Research Group,* Chew EY, SanGiovanni JP,
Ferris FL, Wong WT, Agron E, Clemons TE, Sperduto R, Danis R, Chandra SR, Blodi BA,
Domalpally A, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB,
Klein ML, Friberg TR, Rosenfeld PJ, Toth CA, Bernstein P. Lutein/zeaxanthin for the treatment of
age-related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmol. 2013
Jul;131(7):843-50. doi: 10.1001/jamaophthalmol.2013.4412. PubMed PMID: 23645227.
24. Domalpally A, Danis RP, Chew EY, Clemons TE, Reed S, Sangiovanni JP, Ferris FL 3rd; AgeRelated Eye Disease Study 2 Research Group.* Evaluation of optimized digital fundus reflex
photographs for lens opacities in the age-related eye disease study 2: AREDS2 report 7. Invest
Ophthalmol Vis Sci. 2013 Sep 5;54(9):5989-94. doi: 10.1167/iovs.13-12301. PubMed PMID:
23887802; PubMed Central PMCID: PMC3771555.
25. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC,
Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ; RIDE and RISE Research Group.*
Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month
Results from Two Phase III Trials: RISE and RIDE. Ophthalmology. 2013 Oct;120(10):2013-22.
doi: 10.1016/j.ophtha.2013.02.034. Epub 2013 May 22. PubMed PMID: 23706949.
26. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad
Y, Whitcup SM; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial
of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology.
2014 Oct;121(10):1904-14. doi: 10.1016/j.ophtha.2014.04.024. Epub 2014 Jun 4. PubMed PMID:
24907062.
Non-peer reviewed scientific or medical publications/materials in print or other media
Proceedings of meetings or other non-peer-reviewed research publications
1. Dowling J, Lasater E, Young LHY. Some new approaches and directions in retinal research. In:
Gallego A, Gouras P, Ramon y Cajal S, editors. Neurocircuitry of the retina: a Cajal memorial.
International Congress of Eye Research. New York: Elsevier; 1985. p. 1-18.
Reviews
1.
Damico FM, Young LHY, Gragoudas ES. Melanoma da coroide: onde extamos e para onde
vamos? Revista da Sociedade Brasileira de Retina e Vitreo. 2004; 8: 18. Portuguese.
2. Acharya N, Young LHY. Sustained-release drug implants for the treatment of intraocular disease.
Contemporary Ophthalmology. 2004;21:1. Review.
3. Damico FM, Young LHY, Gragoudas ES. Retinografia panorâmica: uma forma nova de ver a
retina [Retinography overview: a new way of seeing the retina]. Revista da Sociedade de
Brasileira de Retina e Vitreo. September 2005; 9: 8. Portuguese.
4. Kiss S, Young LHY. Current and future trends in ophthalmic drug delivery. Contemporary
Ophthalmology. December 2007; 6(24):1-7.
Chapters
1. Young J, Kwon B, Trapani J, Liu C, Young L. Lymphocyte-mediated cytolysis: role of granule
mediators. In: Harris JR, editor. Blood Cell Biochemistry. New York: Plenum Press; 1991. p. 14362.
2. Young LHY, D'Amico DJ. Acute macular neuroretinopathy. In: Albert DM, Jakobiec FA, editors.
Principles and Practice of Ophthalmology. Philadelphia; London: W.B. Saunders; 1993. p. 926-9.
3. Young LHY, D'Amico DJ. Retinal detachment. In: Albert DM, Jakobiec FA, editors. Principles
and Practice of Ophthalmology. Philadelphia; London: W.B. Saunders; 1993. p. 1084-92.
4. Young LHY, Albert DM. Retinal pigmented epithelium tumors. In: Albert DM, Jakobiec FA,
editors. Principles and Practice of Ophthalmology. Philadelphia; London: W.B. Saunders; 1993. p.
3251-7.
5. Young LHY, D'Amico DJ. Acute macular neuroretinopathy. In: Albert DM, Jakobiec FA, editors.
Principles and Practice of Ophthalmology. 2 ed. Philadelphia; London: W.B. Saunders; 2000. p.
2111 – 3.
6. Kim RY, Young LHY. Bone marrow transplant retinopathy. In: Albert DM, Jakobiec FA, editors.
Principles and Practice of Ophthalmology. 2 ed. Philadelphia; London: W.B. Saunders; 2000. p.
2236 - 40.
7. Young LHY, D'Amico DJ. Retinal detachment. In: Albert DM, Jakobiec FA, editors. Principles
and Practice of Ophthalmology. 2 ed. Philadelphia; London: W.B. Saunders; 2000. p. 2352 – 8.
8. Young LHY, Albert DM. Tumors of the retinal pigment epithelium. In: Albert DM, Jakobiec FA,
editors. Principles and Practice of Ophthalmology. 2 ed. Philadelphia; London: W.B. Saunders;
2000. p. 5065 - 71.
9. Kim RY, Young LHY. Photodynamic therapy for experimental intraocular tumors. In: Gragoudas
ES, Miller JW, Zografos L, editors. Photodynamic Therapy of Ocular Diseases. Philadelphia:
Lippincott Williams & Wilkins; 2004. p. 135-8.
10. Damico FM, Orefice F, Young LHY. Tratamento do edema macular cistoide secundario a uveite
com corticoide intravitreo. In: Orefice F, editor. Uveite clinica e cirurgica. 2 ed. Rio de Janeiro:
Cultura Médica; 2005. p. 341-8.
11. Waheed N, Young LHY. Choroidal effusion. In: Albert DM, Miller JW, T. AD, editors. Albert &
Jakobiec's Principles and Practice of Ophthalmology. 3 ed. Philadelphia: Saunders/Elsevier; 2008.
p. 1281.
12. Sun J, D'Amico DJ, Young LHY. Retinal detachment. In: Albert DM, Miller JW, T. AD, editors.
Albert & Jakobiec's Principles and Practice of Ophthalmology. 3 ed. Philadelphia:
Saunders/Elsevier; 2008. p. 2305.
13. Young LHY, D'Amico DJ. Acute macular neuroretinopathy. In: Albert DM, Miller JW, T. AD,
editors. Albert & Jakobiec's Principles and Practice of Ophthalmology. 3 ed. Philadelphia:
Saunders/Elsevier; 2008. p. 2083.
14. Young LHY, Albert DM. Tumors of the retinal pigment epithelium. In: Albert DM, Miller JW, T.
AD, editors. Albert & Jakobiec's Principles and Practice of Ophthalmology. 3 ed. Philadelphia:
Saunders/Elsevier; 2008. p. 4967.
15. Young LHY. Acute visual disturbance. In: Khaw PT, P. S, editors. ABC of Eyes. 5 ed. London:
Wiley; 2014.
16. Young LHY. General medical disorders and the eye. In: Khaw PT, P. S, editors. ABC of Eyes. 5
ed. London: Wiley; 2014.
Editorials
1. Young LH. Therapy for cytomegalovirus retinitis: still no silver lining. JAMA. 1996 Jan
10;275(2):149-50. PubMed PMID: 8531313.
2. Young LH, D’Amico DJ. Reply to: McDonald HR. Diagnostic and therapeutic challenges. Retina.
2000;20(2):203-7. PubMed PMID: 10783956.
3. Young LH, Brooks HL Jr. Reply to: Mandava N, Bartlett H. Diagnostic and therapeutic
challenges. Retina. 2006 Feb;26(2):214-8. PubMed PMID: 16467681.
4. Young LH. Time critical in infectious uveitis. Ophthalmology Times Europe. 2012;8(3).
Letters to the editor
1. Sheetz MJ, Davis MD, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati
L, PKC-DRS2 Study Group*. Reply to: Sahu AK, Majji AB. Effect of ruboxistaurin on the
visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol
Vis Sci. 2010 Dec;51(12):6890; author reply 6890-1. doi: 10.1167/iovs.09-4106. PubMed PMID:
21123772. (*Member of the investigative team)
2. Garay-Aramburu G; Cabrerizo J; Haller JA; Bandello F; Belfort R Jr; Gillies M; Loewenstein A;
Yoon YH; Li X-Y; Whitcup SM [AGN]; Ozurdex GENEVA Study Group*. Reply to: GarayAramburu G, Cabrerizo J. Intravitreal injection technique. Ophthalmology. 2012
Dec;119(12):2654-5.e1; author reply 2655. doi: 10.1016/j.ophtha.2012.08.033. PubMed PMID:
23207036. (*Member of the investigative team)
Professional educational materials or reports, in print or other media
1. Lancaster Course in Ophthalmology Retina Section Syllabus (1991–present): The syllabus is
designed and available for students of the seven-week Lancaster course, attended by
ophthalmology residents, fellows, and practicing ophthalmologists (national, and international).
Many ophthalmology residency programs use this course as an important part of their residency
teaching. The syllabus is edited and updated each year.
2. Retina Service Teaching File (1993–present): This file was created for the purpose of compiling
rare and interesting retinal cases for teaching purposes. It is available to HMS ophthalmology
residents and Mass. Eye and Ear clinical fellows. New cases are added to this file on a weekly
basis.
Dissertation
1. Young LHY. Monoclonal Antibodies Specific to Horizontal Cells in the Carp Retina. Cambridge,
MA: Harvard University, 1984
Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings
1. Rheaume M-A, Jardeleza MS, Dohlman CH, Young LH. Risk Factors and Incidence of Retinal
Detachment Following Boston Keratoprosthesis: A New Insight Into an Old Problem. ARVO
Meeting Abstracts. 2010 April 11, 2010;51(5):5957.
2. Thanos A, Morizane Y, Trichonas G, Papakostas TD, Young LH, Vavvas D. Role of AMPDependent Kinase in the Function of Retinal Pigment Epithelium. ARVO Meeting Abstracts.
2010 April 11, 2010;51(5):5957.
3. Cordeiro CA, Saeij J, Orefice F, Young LH. Comunicacao entre Toxoplasma gondii e seu
hospeideiro: impacto do genotipo do parasita na resposta inflamatoria.* XIX Congresso
Brasileiro de Prevencao da Cegueira e Reabilitacao Visual. Bahia, Brasil. 9/29/10-10/2/10. *This
paper received the Basic Science Award.
4. Monteiro de Castro V, Cordeiro CA, Vieira ELM, Ribeiro Campo W, Orefice F, Dutra WO,
Teixeira Jr AL, Young LH. Expressao fenotipica das celulas mononucleares CD14+ em pacientes
portadores de retinocoroidite Toxoplasmica ativa. (Phenotypic expression of mononuclear cells in
patients with active Toxoplasmic chorioretinitis).* Congresso Brasileiro de Oftalmologia
(Brazilian Congress of Ophthalmology) 2011. *This paper received the Basic Science Award.
5. Bessa TF, Cordeiro CA, Goncalves RM, Young LH, Campos WR, Orefice F, Teixeira AL.
Increased serum levels of soluble tumor necrosis factor receptor-2 (sTNFR2) in patients with
Toxoplasmic retinochoroiditis. Congresso Brasileiro de Oftalmologia 2011 (Brazilian Congress of
Ophthalmology).
6. Thanos A, Morizane Y, Kayama M, Mantopoulos D, Murakami Y, Young LH, Miller JW,
Vavvas DG. Trp1-cre Revisited: Evidence For Cre-recombinase Toxicity In The Retinal Pigment
Epithelium. ARVO Meeting Abstracts. 2011 April 22, 2011;52(6):908.
7. Cordeiro CA, Orefice F, Saeij J, Young L. Toxoplasma Strain-specific Modulation of Host
Immune Signaling Pathways. ARVO Meeting Abstracts. 2011 April 22, 2011;52(6):2962.
8. Cordeiro CA, Saeij J, Orefice F, Young LH: Toxoplasma strain-specific virulence and
modulation of host immune signaling pathways. The Retina Society and the Societa Italiana della
Retina Annual Meeting, 2011.
9. Cordeiro CA, Vieira EL, Castro VM, Dutra WO, Orefice JL, Costa RA, Campos WR, Orefice F,
Teixeira AL, Young LH. T Cell Immunoregulation In Active Ocular Toxoplasmosis. ARVO
Meeting Abstracts. 2012 March 26, 2012;53(6):1190.
10. Cordeiro CA, Vieira ELM, Castro V, Dutra WO, Orefice JL, Costa RO, Campos WR, Orefice F,
Teixeira AL, Young LHY. Imunoregulacao pelas celulas T na retinocoroidite Toxoplasmica ativa
(T cell Immunoregulation in Active Ocular Toxoplamosis).* Paper presented at Conselho
Brasileiro de Oftalmologia 2012 (Brazilian Congress of Ophthalmology) – *This paper received
The Basic Science Award – 8/10/2012
11. Thanos A, Al Moujahed A, Young L, Vavvas D. Evidence for baseline abnormalities in the retinal
vascular network of Trp1-Cre mice. ARVO Meeting Abstracts. 2013 June 16, 2013;54(6):1781.
12. Miller JM, Yonekawa Y, Eliott D, Kim IK, Kim LA, Loewenstein JI, Sobrin L, Young LH,
Mukai S, and Vavvas DG. Long-term Follow-up and Outcomes in Traumatic Macular Holes.
American Society of Retinal Specialists, August 2013.